Bob Cuddihy, Capsida CEO

CRISPR Ther­a­peu­tics takes a swing at ALS gene edit­ing in dis­cov­ery deal with AAV up­start Cap­si­da

When small biotech Cap­si­da launched just a few months ago, it hit the scene with back­ing from drug gi­ant Ab­b­Vie to chase AAV-de­liv­ered drugs for CNS. Now, the team has earned the sup­port of one of the biggest names in gene edit­ing — and it’s tak­ing on a big chal­lenge right away.

CRISPR Ther­a­peu­tics has signed a deal with Cap­si­da Bio­ther­a­peu­tics, a gene ther­a­py play­er spe­cial­iz­ing in AAV en­gi­neer­ing, to carve out a de­liv­ery mech­a­nism for the com­pa­ny’s gene edit­ing tech in ALS and rare neu­rode­gen­er­a­tive dis­or­der Friedre­ich’s atax­ia, the com­pa­nies said Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.